Maqola

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Massimo ColomboFondazione Humanitas per la RicercaErkin MusabaevResearch Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, UzbekistanUmed IsmailovHepatoсenter, Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, UzbekistanIgor A ZaytsevDepartment of Therapy, Infectious Diseases and Dermatology, Bogomolets National Medical University, Kyiv 01601, UkraineAlexander NersesovDepartment of Gastroenterology and Hepatology, National Research Institute of Cardiology and Internal Diseases, Almaty 050000, KazakhstanIgor Anatoliyevich AnastasiyDepartment Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, UkraineIgor KarpovDepartment Infectious Diseases, Belarus State Medical University, Minsk 220116, BelarusOlga GolubovskaDepartment Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, UkraineKulpash KaliaskarovaHepatology, Ministry of Health, Astana 010000, KazakhstanRavishankar ACMedical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, IndiaSanjay HadigalMedical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India

2019en

Ochiq kirishGibrid

Litsenziya: cc-by-nc

ABI

Annotatsiya

Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of region-specific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3748/wjg.v25.i29.3897

Iqtiboslar va manbalar

0 ta iqtibos160 ta foydalanilgan manba